Pancreatic cancer detected by positron emission tomography with 18F-labelled deoxyglucose

Bares, Roland; Klever, P.; Hellwig, Dirk; Hauptmann, S.; Faß, J.; Hambuechen, U.; Zopp, L.; Mueller, B.; Buell, Udalrich; Schumpèlick, V.

doi:10.1097/00006231-199307000-00013

Cited by 49 publications

(17 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this aspect our data support earlier studies that found a high sensitivity of FDG-PET in detection of pan creatic cancer [12][13][14], Because FDG is not a specific probe and has been reported to accumulate in infectious processes, caution is necessary when FDG is used in can cer patients in whom concomitant infectious processes are suspected or cannot be excluded. Kubota et al [19] also reported high FDG accumulation in macrophages and granulation tissue.…”

Section: Discussionsupporting

confidence: 89%

“…A marked increase in the expression of glucose transporter 1 (Glutl) encoding gene has been recently demonstrated in pancreatic adenocarcinoma, whereas in tissue from chronic pancreatitis this gene was found to be not acti vated [7][8][9][10][11]. Positron emission tomography (PET) with 2-[18F]-fluoro-2-deoxy-D-glucose (FDG) may thus pro vide a direct approach towards detection of pancreatic malignancy and has been successfully used in various studies recently published [12][13][14][15], We thus systematical ly investigated the relation between Glutl encoding gene expression and tumoral glycolysis measured by FDG-PET. We also assessed the performance of FDG-PET for differentiating pancreatic carcinoma from chronic pan creatitis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pathophysiological Basis and Clinical Value of <sup>18</sup>F-Fluorodeoxyglucose and Positron Emission Tomography in Pancreatic Adenocarcinoma

Stollfuß¹,

Grillenberger²,

Fries

et al. 1994

Dig Surg

View full text Add to dashboard Cite

2-[¹⁸F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for detection of pancreatic cancer was evaluated and compared to CT scan. Also the glucose transporter 1 (Glutl) encoding gene expression was determined by Northern blot analysis in 7 patients with pancreatic cancer (PC) and 5 patients with chronic pancreatitis (CP). 73 patients with suspected PC or CP underwent static PET imaging after injection of 250-350 MBq FDG. Focal FDG uptake was considered a sign of malignancy and was calculated using standardized uptake values (60 min p.L). Increased Glutl expression could be demonstrated in all patients with PC and not in patients with CP indicating an important contribution of Glutl to enhanced tumoral glucose consumption. In the visual FDG-PET analysis 41/43 (95%) patients with histologically controlled PC and 27/39 (90%) patients with CP were classified correctly by PET. With CT 33/41 (80%) patients with PC were diagnosed correctly, whereas 7/27 were false-positive (specificity 74%). Thus FDG-PET provided a reliable differentiation of pancreatic adenocarcinoma from chronic pancreatitis.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Introductionmentioning

confidence: 99%

Pathophysiological Basis and Clinical Value of <sup>18</sup>F-Fluorodeoxyglucose and Positron Emission Tomography in Pancreatic Adenocarcinoma

Stollfuß¹,

Grillenberger²,

Fries

et al. 1994

Dig Surg

View full text Add to dashboard Cite

show abstract

“…2.83, 1.94 and 3.55. Later, Klever et al (1992) and Bares et al (1993) reported on several cases of pancre- Fukuda, H. et al (1984) CYRIC Annual Report 1983 atic cancer. Fujiwara et al (1984) were the first to report increased 18 F-FDG uptakes in the malignant lung tumors of 9 patients.…”

Section: Pancreatic Cancermentioning

confidence: 99%

Pioneering and Fundamental Achievements on the Development of Positron Emission Tomography (PET) in Oncology

Fukuda

Kubota

Matsuzawa

2013

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

“…FDG is a positron-emitting radio-tracer that is transported intracellularly via glucose transporters which are highly expressed in pancreatic cancer, then FDG is phosphorylated by hexokinase to FDG-6-PO 4 [33, 34]. However, further metabolism of FDG-6-PO 4 is not possible in the neoplastic cells due to insufficient glucose phosphatase levels and tracer accumulation [34, 35]. …”

Section: Introductionmentioning

confidence: 99%

“…Initial reports that FDG PET was of diagnostic value [21,22,23, 35] were further supported [24,25,26,27,36,37,38,39] to the extent that a consensus conference in Germany concluded that FDG PET had achieved an established clinical role in the diagnosis and staging of pancreatic cancer [40]. More recent studies have however failed to demonstrate any advantage for FDG PET compared to CT [28, 29, 31, 41, 42].…”

Section: Introductionmentioning

confidence: 99%

Positron Emission Tomography Does Not Add to Computed Tomography for the Diagnosis and Staging of Pancreatic Cancer

Lytras¹,

Connor²,

Bosonnet³

et al. 2005

Dig Surg

View full text Add to dashboard Cite

Background: Positron emission tomography (PET) has been proposed for pancreatic cancer diagnosis and staging. Methods: 112 patients with suspected pancreatic cancer underwent ¹⁸F-fluoro-2-deoxy-D-glucose gamma camera PET and computed tomography (CT), of whom 62 also had laparoscopic ultrasonography and 70 underwent abdominal exploration for potential resection. The final diagnosis was malignancy in 78 and benign disease in 34 patients (25 with chronic pancreatitis). Results: The diagnostic sensitivity and specificity for PET were 73 and 60% compared to 89 and 65% for CT respectively (Cohen’s ĸ = 0.59). In 30 patients CT was equivocal with cancer in 14 and benign disease in 16. PET correctly diagnosed 13 of these patients (cancer in 6 and benign disease in 7), interpreted 4 as equivocal (cancer in 3 and benign disease in 1) but was incorrect in the remaining 13 patients (cancer in 5 and benign disease in 8). The sensitivity and specificity for detecting small volume metastatic disease were 20 and 94% for CT and 22 and 91% for PET, respectively. Conclusion: PET had a similar accuracy to that of CT for imaging pancreatic cancer but it did not provide any additional information in patients with equivocal CT findings and currently would seem of little benefit for the staging of pancreatic cancer.

show abstract

Pancreatic cancer detected by positron emission tomography with 18F-labelled deoxyglucose

Cited by 49 publications

References 0 publications

Pathophysiological Basis and Clinical Value of <sup>18</sup>F-Fluorodeoxyglucose and Positron Emission Tomography in Pancreatic Adenocarcinoma

Pathophysiological Basis and Clinical Value of <sup>18</sup>F-Fluorodeoxyglucose and Positron Emission Tomography in Pancreatic Adenocarcinoma

Pioneering and Fundamental Achievements on the Development of Positron Emission Tomography (PET) in Oncology

Positron Emission Tomography Does Not Add to Computed Tomography for the Diagnosis and Staging of Pancreatic Cancer

Contact Info

Product

Resources

About